Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1970;41:579-588

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MANCHESTER, J. H.
Right arrow Articles by GORLIN, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MANCHESTER, J. H.
Right arrow Articles by GORLIN, R.

(Circulation. 1970;41:579.)
© 1970 American Heart Association, Inc.


Effects of Glucagon on Myocardial Oxygen Consumption and Coronary Blood Flow in Man and in Dog

JOEL H. MANCHESTER M.D.; WILLIAM W. PARMLEY M.D.; JACK M. MATLOFF M.D.; A. JAMES LEIDTKE M.D.; PAUL J. LARAIA M.D.; MICHAEL V. HERMAN M.D.; EDMUND H. SONNENBLICK M.D.; RICHARD GORLIN M.D.

The effects of intravenous administration of glucagon (50 µg/kg) on left coronary blood flow and myocardial oxygen consumption were studied in nine patients during diagnostic cardiac catheterization and in six open-chested anesthetized dogs. Coronary blood flow was measured with the 133Xe washout technic in man, and with an electromagnetic flowmeter placed around the left anterior descending coronary artery in the dogs. In the patients, glucagon produced a 31% increase in coronary blood flow and a 29% increase in myocardial oxygen consumption, with no change in coronary arteriovenous (A-V) O2 difference across the heart. In the dogs glucagon produced a 114% increase in coronary blood flow and a 131% increase in myocardial oxygen consumption, again with no change in coronary A-V O2 difference. Thus glucagon is a secondary coronary vasodilator in both man and dog. The modest chronotropic and inotropic effects of glucagon observed in man were only half as great as those observed in the dog. Part or all of this difference in dose-response relationship between the two species may be related to the different experimental conditions of the study.


Key Words: Coronary A-V O2 difference • Coronary vascular resistance • Pressure-time per minute • Secondary coronary vasodilator • Left ventricular work • 133Xe washout

Submitted on October 27, 1969
Accepted on December 2, 1969




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C. Korvald, O. P. Elvenes, L. M. Ytrebo, D. G. Sorlie, and T. Myrmel
Oxygen-wasting effect of inotropy  in the "virtual work model"
Am J Physiol Heart Circ Physiol, April 1, 1999; 276(4): H1339 - H1345.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
R. J. Kones, D. H. Dombeck, and J. H. Phillips
Glucagon in Cardiogenic Shock
Angiology, September 1, 1972; 23(9): 525 - 535.
[PDF]